Radiomic fEatures of Pancreas From Contrast Enhanced CT Image Predict One-Year RecUrrence Risk of Acute PancReatitis
NCT05778929 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 694
Last updated 2023-03-22
Summary
One-year recurrence rate of acute pancreatitis at about 20%. 36% of the patients with recurrent acute pancreatitis will develop into chronic pancreatitis. In addition to negative impact on patient's quality of life, chronic pancreatitis is also associated with the occurrence of pancreatic cancer. The etiology of recurrent acute pancreatitis (RAP) can be divided into mechanical obstructive factors (e.g. cholelithiasis, cholestasis), metabolic abnormality and toxic substance factors (e.g. hyperlipidemia and alcoholism), and other or idiopathic factors. At present, the diagnosis and treatment of RAP remains highly challenging. Early identification and intervention on risk factors of recurrence will be effective in reducing incidence and improving prognosis.
Contrast-enhanced Computed Tomography (CT) can not only provide more imaging information and further assess the severity of acute pancreatitis, but also aid in the differentiation of other diseases associated with acute abdominal pain. In addition, radiomics based on raw radiographic data has become a research hotspot in recent years. The purpose of this study is to establish and validate a deep learning model based on high concentration iopromide-enhanced abdominal CT images which is designed to predict the recurrence of pancreatitis in patients with first episode of pancreatitis within the 1-year follow-up period.
Conditions
- Pancreatitis, Chronic
Interventions
- DIAGNOSTIC_TEST
-
Radiomics Model
A total of 694 consecutive eligible patients with first episode of "acute pancreatitis" that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study). Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status.
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-01
- Primary Completion
- 2025-04-01
- Completion
- 2025-04-01
More Related Trials
-
PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa
NCT07252076 ·Status: RECRUITING
-
Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma
NCT02028377 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
NCT05340569 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer
NCT02550847 ·Status: UNKNOWN
-
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
NCT03318497 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
NCT00885248 ·Status: UNKNOWN
-
Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma
NCT02775786 ·Status: COMPLETED ·Phase: NA
-
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275 ·Status: RECRUITING
-
Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer Index
NCT05063019 ·Status: UNKNOWN ·Phase: NA
-
18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
NCT05884463 ·Status: COMPLETED ·Phase: NA
-
A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established
NCT06614179 ·Status: RECRUITING
-
Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.
NCT03202199 ·Status: UNKNOWN ·Phase: NA
-
18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study
NCT03352037 ·Status: COMPLETED ·Phase: NA
-
The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.
NCT02777463 ·Status: COMPLETED
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
NCT03967951 ·Status: COMPLETED
-
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT04700488 ·Status: SUSPENDED ·Phase: NA
-
Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic Adenocarcinoma
NCT05023291 ·Status: TERMINATED ·Phase: NA
-
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
NCT07102056 ·Status: NOT_YET_RECRUITING
-
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
NCT05875753 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
NCT03914950 ·Status: COMPLETED ·Phase: NA
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 ·Status: RECRUITING
-
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
NCT06126159 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling
NCT02944006 ·Status: UNKNOWN
-
MRE for Diagnosis of Pancreatic Masses
NCT06526442 ·Status: RECRUITING